

CHAMPIONS ONCOLOGY, INC.
Form 4
September 14, 2016

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
ACKERMAN JOEL

2. Issuer Name and Ticker or Trading Symbol
CHAMPIONS ONCOLOGY, INC.
[CSBR]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction
(Month/Day/Year)

Director 10% Owner
 Officer (give title below) Other (specify below)

Chief Executive Officer

C/O CHAMPIONS ONCOLOGY, INC., ONE UNIVERSITY PLACE, SUITE 307

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

HACKENSACK, NJ 07601

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
				Code	V	Amount	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: CHAMPIONS ONCOLOGY, INC. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Security (Instr. 3 and 4)	
					V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount
Option to purchase Common Stock	\$ 2.1	07/21/2016		A		150,795		<u>(1)</u>	10/25/2025	Common Stock	150,795
Option to purchase Common Stock	\$ 2.1	07/21/2016		A		150,795		<u>(1)</u>	10/25/2025	Common Stock	150,795
Option to purchase Common Stock	\$ 2.1	07/21/2016		A		101,521		<u>(3)</u>	11/05/2023	Common Stock	101,521
Option to purchase Common Stock	\$ 2.1	07/21/2016		A		101,521		<u>(4)</u>	11/05/2023	Common Stock	101,521
Option to purchase Common Stock	\$ 2.1	07/21/2016		A		14,552		<u>(1)</u>	11/05/2023	Common Stock	14,552
Option to purchase Common Stock	\$ 2.1	07/21/2016		A		88,470		<u>(1)</u>	11/01/2024	Common Stock	88,470
Option to purchase Common Stock	\$ 2.1	07/21/2016		A		94,405		<u>(5)</u>	11/01/2025	Common Stock	94,405
Option to purchase Common Stock	\$ 4.92	07/21/2016		D		182,580		<u>(6)</u>	10/25/2020	Common Stock	182,580
Option to purchase Common Stock	\$ 4.92	07/21/2016		D		182,580		<u>(4)</u>	10/25/2020	Common Stock	182,580
Option to purchase	\$ 4.92	07/21/2016		D		112,331		<u>(7)</u>	11/05/2023	Common Stock	112,331

Common Stock									
Option to purchase Common Stock	\$ 4.92	07/21/2016	D	112,331	(4)	11/05/2023	Common Stock	11	
Option to purchase Common Stock	\$ 4.92	07/21/2016	D	16,101	(6)	11/05/2023	Common Stock	1	
Option to purchase Common Stock	\$ 4.92	07/21/2016	D	96,283	(6)	11/01/2024	Common Stock	9	
Option to purchase Common Stock	\$ 4.55	07/21/2016	D	100,765	(8)	11/01/2025	Common Stock	10	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ACKERMAN JOEL C/O CHAMPIONS ONCOLOGY, INC. ONE UNIVERSITY PLACE, SUITE 307 HACKENSACK, NJ 07601	X		Chief Executive Officer	

Signatures

/s/ Joel Ackerman 09/14/2016

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Fully vested upon grant.
- (2) The reporting person agreed to the cancellation of options granted to him on March 16, 2015 and November 19, 2015 in exchange for new options having a lower exercise price.
- (3) Vested as to 74,529 shares on grant; remainder to vest on November 5, 2016.
- (4) Vesting to occur upon completion of performance criteria that have not been set.
- (5) Vested as to 70,804 shares on grant; remainder to vest on October 31, 2016.
- (6) Fully Vested.
- (7) Vested as to 84,249 shares on grant; remainder to vest on November 5, 2016.

Edgar Filing: CHAMPIONS ONCOLOGY, INC. - Form 4

(8) Vested as to 75,574 shares on grant; remainder to vest on October 31, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.